iShares Biotechnology ETFiShares Biotechnology ETFiShares Biotechnology ETF

iShares Biotechnology ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪6.68 B‬USD
Fund flows (1Y)
‪−673.97 M‬USD
Dividend yield (indicated)
0.33%
Discount/Premium to NAV
1.03%

About iShares Biotechnology ETF


Issuer
Blackrock Finance, Inc.
Brand
iShares
Expense ratio
0.45%
Home page
Inception date
Feb 5, 2001
Index tracked
NYSE Biotechnology (TR)
Management style
Passive
IBB tracks an index of US biotechnology companies listed on the major US exchanges. This includes companies engaged in the research and development of therapeutic treatments but are not focused on the commercialization and mass production of pharmaceutical drugs. This also includes companies that are engaged in the production of tools or systems that enable biotechnology processes. IBB includes companies of all capitalizations, and weights using a modified market-cap methodology. Individual holdings are subject to capping requirements, 8% on the five largest constituents and 4% for the remaining. The index is rebalanced quarterly and fully reconstituted annually in December. Prior to June 21, 2021, the fund was named iShares Nasdaq Biotechnology ETF and tracked the NASDAQ Biotechnology Index.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Biotechnology
Strategy
Vanilla
Weighting scheme
Tiered
Selection criteria
Market cap

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of November 20, 2024
Exposure type
StocksBonds, Cash & Other
Health Technology
Stocks99.86%
Health Technology94.05%
Health Services3.77%
Commercial Services2.04%
Bonds, Cash & Other0.14%
Cash0.14%
Miscellaneous0.00%
Futures−0.00%
Stock breakdown by region
100%
North America100.00%
Latin America0.00%
Europe0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows